Dr. Zhang on the Importance of Adjuvant Clinical Trials in RCC

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the importance of clinical trials in the adjuvant setting of renal cell carcinoma (RCC).

Although the utility of adjuvant therapy in the treatment of RCC is still contested, Zhang says that participation in clinical trials is beneficial.

Adjuvant therapy may delay time to disease recurrence, and in a setting where there is no standard of care, Zhang encourages community urologists and primary care physicians to recommend their patients to clinical trials of adjuvant therapy.